The Global Transthyretin Amyloid Cardiomyopathy Treatment Market is estimated to be valued at US$ 1943.69 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031.Key players operating in the Transthyretin Amyloid Cardiomyopathy Treatment market are DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin, Silk€TMn, HoMedics USA LLC, PMD Beauty, Dermaglow,...
The global transthyretin amyloid cardiomyopathy treatment market is primarily driven by the increasing prevalence of ATTR-CM disease globally. Transthyretin amyloid cardiomyopathy, also known as ATTR-CM, is a rare, progressive, and frequently life-threatening heart disease caused by abnormal deposits of amyloid protein consisting of misfolded transthyretin (TTR) in the heart. ATTR-CM treatment...